O

nce again, lawmakers are pressuring a company that sells a version of naloxone, a decades-old drug that is widely used to reverse the effect of opioid and heroin overdoses, to explain its pricing.

A group of 31 US senators — all Democrats — sent a letter on Wednesday to Kaleo seeking pricing data about its Evzio treatment, along with production costs, donation programs, and reimbursement from federal health care programs. The letter was sent after the company recently began selling a stronger version of the antidote at an even higher price than an older version that contains less medicine.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories